Swedbank AB Reduces Holdings in DexCom, Inc. $DXCM

Swedbank AB lowered its position in DexCom, Inc. (NASDAQ:DXCM) by 4.1% during the third quarter, HoldingsChannel reports. The firm owned 223,978 shares of the medical device company’s stock after selling 9,564 shares during the period. Swedbank AB’s holdings in DexCom were worth $15,071,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. GAMMA Investing LLC raised its position in shares of DexCom by 2.5% in the third quarter. GAMMA Investing LLC now owns 7,043 shares of the medical device company’s stock valued at $474,000 after buying an additional 169 shares during the last quarter. Meiji Yasuda Asset Management Co Ltd. grew its stake in DexCom by 3.2% during the 1st quarter. Meiji Yasuda Asset Management Co Ltd. now owns 6,019 shares of the medical device company’s stock valued at $411,000 after acquiring an additional 187 shares in the last quarter. Integrated Wealth Concepts LLC raised its holdings in DexCom by 6.3% in the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after acquiring an additional 196 shares during the last quarter. STF Management LP lifted its stake in DexCom by 5.5% in the 2nd quarter. STF Management LP now owns 4,041 shares of the medical device company’s stock worth $353,000 after purchasing an additional 211 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB boosted its holdings in shares of DexCom by 23.9% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 1,125 shares of the medical device company’s stock worth $98,000 after purchasing an additional 217 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Up 0.2%

Shares of NASDAQ:DXCM opened at $67.57 on Friday. The company has a market capitalization of $26.35 billion, a price-to-earnings ratio of 37.54, a PEG ratio of 1.45 and a beta of 1.51. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $93.25. The business has a 50-day moving average price of $64.07 and a 200 day moving average price of $73.19. The company has a current ratio of 1.56, a quick ratio of 1.38 and a debt-to-equity ratio of 0.45.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.04. DexCom had a net margin of 15.96% and a return on equity of 30.65%. The company had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.18 billion. During the same quarter last year, the firm posted $0.45 earnings per share. DexCom’s revenue was up 21.6% compared to the same quarter last year. Sell-side analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Stifel Nicolaus started coverage on DexCom in a report on Tuesday, October 21st. They issued a “buy” rating and a $85.00 price target for the company. Robert W. Baird set a $82.00 target price on DexCom in a research note on Friday, October 31st. UBS Group lowered their price target on shares of DexCom from $106.00 to $95.00 and set a “buy” rating on the stock in a research report on Monday, November 3rd. Piper Sandler set a $75.00 price objective on shares of DexCom and gave the stock a “buy” rating in a research report on Friday, October 31st. Finally, Oppenheimer downgraded shares of DexCom from an “outperform” rating to a “market perform” rating in a research note on Monday, September 8th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and a consensus target price of $86.61.

Insider Buying and Selling

In other news, Director Bridgette P. Heller sold 1,012 shares of the firm’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $58.07, for a total transaction of $58,766.84. Following the completion of the transaction, the director directly owned 27,031 shares in the company, valued at $1,569,690.17. This trade represents a 3.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Richard Alexander Collins sold 3,948 shares of DexCom stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $55.17, for a total transaction of $217,811.16. Following the completion of the transaction, the director owned 37,994 shares of the company’s stock, valued at $2,096,128.98. This trade represents a 9.41% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 7,866 shares of company stock valued at $448,177. Company insiders own 0.32% of the company’s stock.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.